Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Vaccine Revaccination Schedules in Adults >= 60 Years
NCT04732871Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Feb 2021; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04732871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732871.